Patents by Inventor John P. Cooke

John P. Cooke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10857216
    Abstract: The invention features methods and kits use in for preventing and treating vulvovaginal candidiasis (VVC), in particular, recurrent VVC.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: December 8, 2020
    Assignees: NovaDigm Therapeutics, Inc., Los Angeles Biomedical Institute at Harbor-UCLA Medical Center
    Inventors: John E. Edwards, Jr., Scott G. Filler, John P. Hennessey, Jr., Michael Timothy Cooke, Jack D. Sobel
  • Publication number: 20200338056
    Abstract: Provided herein are proton pump inhibitors that promote cellular senescence, methods of using the proton pump inhibitors to promote cellular senescence and compositions and kits comprising the proton pump inhibitors. Also provided are methods of screening for candidate agents that promote senescence or inhibit senescence.
    Type: Application
    Filed: March 23, 2016
    Publication date: October 29, 2020
    Applicant: THE METHODIST HOSPITAL SYSTEM
    Inventors: John P. COOKE, Gautham YEPURI, Yohannes Tsegai GHEBRE
  • Patent number: 10760061
    Abstract: The nuclear reprogramming of somatic cells with mRNA encoding reprogramming factors is shown to be greatly accelerated by activation of innate immune responses in the somatic cell. Methods of activating innate immunity include activation of PKR, of toll-like receptors, e.g. TLR3, etc. In some embodiments the mRNA provides the activator of innate immunity.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: September 1, 2020
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: John P. Cooke, Eduard Yakubov
  • Patent number: 10264974
    Abstract: Disclosed are methods for imaging lumen-forming structures such as blood vessels using near-infrared fluorescence in the NIR-II region of 1000-1700 nm. The fluorescence is created by excitation of solubilized nano-structures that are delivered to the structures, such as carbon nanotubes, quantum dots or organic molecular fluorophores attached to hydrophilic polymers. These nanostructures fluoresce in the NIR-II region when illuminated through the skin and tissues. Fine anatomical vessel resolution down to ?30 ?m and high temporal resolution up to 5-10 frames per second is obtained for small-vessel imaging with up to 1 cm penetration depth in mouse hind limb, which compares favorably to tomographic imaging modalities such as CT and MRI with much higher spatial and temporal resolution, and compares favorably to scanning microscopic imaging techniques with much deeper penetration.
    Type: Grant
    Filed: November 20, 2012
    Date of Patent: April 23, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Guosong Hong, Jerry Chung-yu Lee, Ngan Fong Huang, John P. Cooke, Hongjie Dai
  • Patent number: 10238769
    Abstract: Embodiments of the present invention relate to a therapeutic device (graft) comprising a collagen membrane having an aligned uniaxial or biaxial structure such that mammalian cells plated on the membrane align mainly along the direction of the collagen fibrils. In a further aspect, a graft comprising a substantially tubular body, wherein the body has an exterior surface, an interior surface, and at least one lumen extending therethrough such that a fluid flow through the lumen can direct mammalian cell migration. In a further aspect, mammalian cells or growth and angiogenic factors can be optionally attached to the exterior and/or interior surface of the substantially tubular body. In various aspects, the graft can be used as a vascular prosthesis, a stent, or a nerve regeneration scaffold. Methods of preparing and implanting same are also provided.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: March 26, 2019
    Assignees: Fibralign Corporation, The Board of Trustees of the Leland Stanford Junior University
    Inventors: Michael V. Paukshto, John P. Cooke, Tatiana S. Zaitseva, Ngan F. Huang, Gerald G. Fuller, George R. Martin
  • Publication number: 20180360924
    Abstract: Disclosed is a method for rejuvenating cells, such as chondrocytes, that involves contacting the cell with a composition comprising a synthetic ribonucleic acid comprising at least one modified nucleoside encoding a telomerase reverse transcriptase, and a composition comprising an anti-inflammatory agent, in amounts effective to extend at least one telomere in the cell.
    Type: Application
    Filed: November 23, 2016
    Publication date: December 20, 2018
    Inventors: Mir Timo Zadegh NAZARI-SHAFTI, John P. COOKE
  • Patent number: 9738873
    Abstract: The nuclear reprogramming of somatic cells with mRNA encoding reprogramming factors is shown to be greatly accelerated by activation of innate immune responses in the somatic cell. Methods of activating innate immunity include activation of PKR, of toll-like receptors, e.g. TLR3, etc. In some embodiments the mRNA provides the activator of innate immunity.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: August 22, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: John P. Cooke, Eduard Yakubov
  • Publication number: 20170204376
    Abstract: The nuclear reprogramming of somatic cells with mRNA encoding reprogramming factors is shown to be greatly accelerated by activation of innate immune responses in the somatic cell. Methods of activating innate immunity include activation of PKR, of toll-like receptors, e.g. TLR3, etc. In some embodiments the mRNA provides the activator of innate immunity.
    Type: Application
    Filed: April 5, 2017
    Publication date: July 20, 2017
    Inventors: John P. Cooke, Eduard Yakubov
  • Publication number: 20150297086
    Abstract: Disclosed are methods for imaging lumen-forming structures such as blood vessels using near-infrared fluorescence in the NIR-II region of 1000-1700 nm. The fluorescence is created by excitation of solubilized nano-structures that are delivered to the structures, such as carbon nanotubes, quantum dots or organic molecular fluorophores attached to hydrophilic polymers. These nanostructures fluoresce in the NIR-II region when illuminated through the skin and tissues. Fine anatomical vessel resolution down to ?30 ?m and high temporal resolution up to 5-10 frames per second is obtained for small-vessel imaging with up to 1 cm penetration depth in mouse hind limb, which compares favorably to tomographic imaging modalities such as CT and MRI with much higher spatial and temporal resolution, and compares favorably to scanning microscopic imaging techniques with much deeper penetration.
    Type: Application
    Filed: November 20, 2012
    Publication date: October 22, 2015
    Inventors: Guosong Hong, Jerry Chung-yu Lee, Ngan Fong Huang, John P. Cooke, Hongjie Dai
  • Publication number: 20150238472
    Abstract: The present disclosure provides DDAH modulators. Thus, the present disclosure provides a method of treating a patient suffering from a disorder characterized by excessive NO production and/or elevated DDAH activity, the method comprising administering to said patient an effective amount of a compound of one of formulae I-X. The present disclosure also provides a pharmaceutical composition comprising a compound of one of formulae I-X.
    Type: Application
    Filed: March 20, 2015
    Publication date: August 27, 2015
    Inventors: Yohannes T. Ghebremariam, John P. Cooke
  • Publication number: 20150225699
    Abstract: The nuclear reprogramming of somatic cells with mRNA encoding reprogramming factors is shown to be greatly accelerated by activation of innate immune responses in the somatic cell. Methods of activating innate immunity include activation of PKR, of toll-like receptors, e.g. TLR3, etc. In some embodiments the mRNA provides the activator of innate immunity.
    Type: Application
    Filed: February 6, 2015
    Publication date: August 13, 2015
    Inventors: John P. Cooke, Eduard Yakubov
  • Patent number: 9011882
    Abstract: The present disclosure provides DDAH modulators. Thus, the present disclosure provides a method of treating a patient suffering from a disorder characterized by excessive NO production and/or elevated DDAH activity, the method comprising administering to said patient an effective amount of a compound of one of formulae I-X. The present disclosure also provides a pharmaceutical composition comprising a compound of one of formulae I-X.
    Type: Grant
    Filed: February 13, 2013
    Date of Patent: April 21, 2015
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Yohannes T. Ghebremariam, John P. Cooke
  • Publication number: 20140242347
    Abstract: Embodiments of the present invention relate to a therapeutic device (graft) comprising a collagen membrane having an aligned uniaxial or biaxial structure such that mammalian cells plated on the membrane align mainly along the direction of the collagen fibrils. In a further aspect, a graft comprising a substantially tubular body, wherein the body has an exterior surface, an interior surface, and at least one lumen extending therethrough such that a fluid flow through the lumen can direct mammalian cell migration. In a further aspect, mammalian cells or growth and angiogenic factors can be optionally attached to the exterior and/or interior surface of the substantially tubular body. In various aspects, the graft can be used as a vascular prosthesis, a stent, or a nerve regeneration scaffold. Methods of preparing and implanting same are also provided.
    Type: Application
    Filed: October 11, 2012
    Publication date: August 28, 2014
    Inventors: Michael V. Paukshto, John P. Cooke, Tatiana S. Zaitseva, Ngan F. Huang, Gerald G. Fuller, George R. Martin
  • Publication number: 20140187519
    Abstract: Provided herein are diagnostic markers and uses thereof for predicting if a subject is at risk of a major adverse event. In particular, one aspect provided herein relates to methods to determine if a subject is at risk of having a major adverse effect by measuring at least 2, or at least 3 of the biomarkers beta 2 microglobulin, c-reactive protein and cystatin C.
    Type: Application
    Filed: December 3, 2013
    Publication date: July 3, 2014
    Applicant: The Board Of Trustees Of The Leland Stanford Junior University
    Inventors: John P. Cooke, Nicholas J. Leeper, Kevin Nead
  • Patent number: 8709735
    Abstract: The present invention provides ?2 microglobulin as a biomarker for qualifying or assessing peripheral artery disease in a subject.
    Type: Grant
    Filed: January 16, 2013
    Date of Patent: April 29, 2014
    Assignees: Vermillion, Inc., Board of Trustees of of the Leland Stanford Junior University
    Inventors: John P. Cooke, Eric T. Fung, Elichiro Kimura
  • Publication number: 20130260389
    Abstract: The present invention provides ?2 microglobulin as a biomarker for qualifying or assessing peripheral artery disease in a subject.
    Type: Application
    Filed: January 16, 2013
    Publication date: October 3, 2013
    Applicants: Board of Trustees of the Leland Stanford Junior Un University, Vermillion, Inc.
    Inventors: John P. Cooke, Eric T. Fung, Eiichiro Kimura
  • Patent number: 8377646
    Abstract: The present invention provides ?2 microglobulin as a biomarker for qualifying or assessing peripheral artery disease in a subject.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: February 19, 2013
    Assignees: Vermillion, Inc., Board of Trustees of the Leland Standford Junior University
    Inventors: John P. Cooke, Eric T. Fung, Eiichiro Kimura
  • Publication number: 20120208232
    Abstract: Compositions and methods are provided for the cell-free synthesis of active reprogramming factor polypeptides. The reprogramming factors may be synthesized as fusion proteins comprising a permeant domain, such as polyarginme. The cell free-synthesis may be conducted at about 25 C in a bacterial cell extract from genetically alterd cells having decreased endogenous protease activity Further, the proteins may comprise a fusion partner which enhances solubility and may be refolded on a column.
    Type: Application
    Filed: July 14, 2010
    Publication date: August 16, 2012
    Inventors: William Yang, Kedar Patel, Yohannes T. Ghebremariam, Ji Eun Lee, Hann-Chung Wong, John P. Cooke, James Robert Swartz
  • Patent number: 8236772
    Abstract: The present invention provides methods of modulating angiogenesis in an individual, as well as methods of identifying a candidate agent that modulates angiogenesis, where such methods involve modulating and identifying agents that modulate expression of gene products of a subset of genes concordantly-regulated by agonists of nicotinic acetylcholine receptor (nAChR), bFGF receptor, and VEGF receptor.
    Type: Grant
    Filed: September 15, 2006
    Date of Patent: August 7, 2012
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: John P. Cooke, Martin Ng, Jenny C. Wu, Edwin Chang
  • Patent number: 8227201
    Abstract: The present invention relates to use of ?-2-microglobulin (B2M or ?2M) and C-reactive protein (CRP) levels as biomarkers of peripheral artery disease and/or atherosclerosis.
    Type: Grant
    Filed: June 26, 2008
    Date of Patent: July 24, 2012
    Assignee: Board of Trustees of the Leland Stanford Junior University
    Inventors: John P. Cooke, Andrew Wilson